Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat.

Tetraphase's proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates.

Tetraphase was founded in 2006 & is based in Watertown, Massachusetts, United States.

Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people.  

Tetraphase has developed a robust antibiotics platform that offers the potential to dramatically improve the treatment of serious bacterial infections, particularly those involving the toughest Gram-negative, multidrug-resistant bacteria.



  • Year founded: 2006
  • Funding Info: $95M in 4 funding rounds (Last funding type: Series C)
  • Yearly Revenue: $10M-$20M (2018)
  • Employee Size: 51-200
  • Business Valuation: Mkt Cap: $69.18M as of Jan 18, 2019 - Valued $138.6M at IPO on Mar 20, 2013
  • City/Town: Watertown
  • State: Massachusetts
  • Country: United States
Related businesses